Ipca Laboratories receives USFDA’s EIR for Tarapur API facility
The EIR classifies the manufacturing facility as ‘Voluntary Action Indicated’
Ipca Laboratories has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility situated at Tarapur. The EIR classifies the manufacturing facility as ‘Voluntary Action Indicated’ (VAI) and that this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).
The USFDA had conducted an inspection at said facility from December 1, 2025 to December 5, 2025.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations.
